News
Topline results were announced from two phase 3 trials evaluating itepekimab in former smokers with inadequately controlled COPD.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback